Skip to main content

Table 5 Five year relative survival and relative excess risk of death of female breast cancer patients by tumor characteristics, systemic treatment and age

From: Provision of breast cancer care and survival in Germany – results from a population-based high resolution study from Saarland

Patient/tumor characteristics Treatment Provision N RSa SE RERb 95% CI p-value
Nodal positive tumor, ER + or PgR+ Chemotherapy + antiestrogen treatment yes 781 99.0 3.7 REF   
   no 506 86.2 3.1 1.45 0.78-2.68 0.239
Nodal positive tumor, ER + or PgR+, age 15–69 years Chemotherapy + antiestrogen treatment yes 701 92.0 1.8    
   no 264 88.3 3.0    
Nodal positive tumor, ER + or PgR+, age > =70 years Chemotherapy + antiestrogen treatment yes 80 95.0 8.9    
   no 242 83.5 5.5    
Nodal positive tumor, ER- and PgR- Chemotherapy yes 238 54.3 6.3 REF   
   no 30 28.5 9.7 2.89 1.46-5.71 0.002
Nodal negative tumor, ER- and PgR- Chemotherapy yes 310 94.9 5.5 REF   
   no 104 83.9 6.2 0.80 0.20-3.18 0.751
ER + or PgR+ Antiestrogen treatment yes 3663 97.1 1.3 REF   
   no 536 85.6 3.8 1.75 0.99-3.07 0.053
ER + or PgR+, age 15–69 years Antiestrogen treatment yes 2664 96.8 0.7    
   no 401 89.4 2.4    
ER + or PgR+, age > =70 years Antiestrogen treatment yes 999 96.2 2.5    
   no 135 81.8 7.4    
HER2/neu positive tumor Targeted therapy yes 198 89.3 9.5 REF   
   no 509 84.4 4.1 2.17 0.91-5.14 0.080
  1. Five year relative survival and relative excess risk of death of female breast cancer patients (ICD-10: C50) from Saarland estimated for calendar period 2005–2009 by tumor characteristics, systemic treatment and age. N: number of patients contributing survival experience; RS: point estimate of 5-year relative survival; SE: standard error of RS; RER: relative excess risk (of death); CI: confidence interval; a) except for age group-specific survival, age standardized estimates were derived using the ICSS weights; b) adjusted for age (15–49, 50–69, > = 70 years), tumor size (<5 cm (T1/T2), > = 5 cm (T3/T4)), lymph node involvement (negative, N1, N2/N3), histologic grade (G1/G2, G3/G4), hormone receptor status (ER + or PgR+, ER- and PgR-) and HER2/neu expression (positive, negative); including patients with microscopically verified tumors and available information on age, T, N, histologic grade, hormone receptor status, HER2/neu expression and provision of the respective systemic treatment; patients presenting with distant metastases or DCO notified tumors were excluded.